Comparison of the in vitro and in vivo stability of a succinimide intermediate observed on a therapeutic IgG1 molecule

References

• Reichert JM. Which are the antibodies to watch in 2012?. MAbs 2012; 4:1 - 3; http://dx.doi.org/10.4161/mabs.4.1.18719; PMID: 22327425
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 2011; 3:76 - 99; http://dx.doi.org/10.4161/mabs.3.1.13895; PMID: 21051951
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2010. MAbs 2010; 2:84 - 100; http://dx.doi.org/10.4161/mabs.2.1.10677; PMID: 20065640
   PubMed Web of Science ®Google Scholar
• Dhimolea E, Reichert JM. World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA. MAbs 2012; 4:4 - 13; http://dx.doi.org/10.4161/mabs.4.1.18821; PMID: 22327426
   PubMedGoogle Scholar
• Correia IR. Stability of IgG isotypes in serum. MAbs 2010; 2:221 - 32; http://dx.doi.org/10.4161/mabs.2.3.11788; PMID: 20404539
   PubMed Web of Science ®Google Scholar
• Robinson NE, Robinson AB. Molecular clocks. Proc Natl Acad Sci U S A 2001; 98:944 - 9; http://dx.doi.org/10.1073/pnas.98.3.944; PMID: 11158575
   PubMed Web of Science ®Google Scholar
• Robinson NE, Robinson AB. Deamidation of human proteins. Proc Natl Acad Sci U S A 2001; 98:12409 - 13; http://dx.doi.org/10.1073/pnas.221463198; PMID: 11606750
   PubMed Web of Science ®Google Scholar
• Robinson NE. Protein deamidation. Proc Natl Acad Sci U S A 2002; 99:5283 - 8; http://dx.doi.org/10.1073/pnas.082102799; PMID: 11959979
   PubMed Web of Science ®Google Scholar
• Sreedhara A, Cordoba A, Zhu Q, Kwong J, Liu J. Characterization of the isomerization products of aspartate residues at two different sites in a monoclonal antibody. Pharm Res 2012; 29:187 - 97; http://dx.doi.org/10.1007/s11095-011-0534-2; PMID: 21809161
   PubMed Web of Science ®Google Scholar
• Zhang J, Yip H, Katta V. Identification of isomerization and racemization of aspartate in the Asp-Asp motifs of a therapeutic protein. Anal Biochem 2011; 410:234 - 43; http://dx.doi.org/10.1016/j.ab.2010.11.040; PMID: 21130067
   PubMed Web of Science ®Google Scholar
• Cournoyer JJ, Pittman JL, Ivleva VB, Fallows E, Waskell L, Costello CE, et al. Deamidation: Differentiation of aspartyl from isoaspartyl products in peptides by electron capture dissociation. Protein Sci 2005; 14:452 - 63; http://dx.doi.org/10.1110/ps.041062905; PMID: 15659375
   PubMed Web of Science ®Google Scholar
• Cournoyer J, O’Connor P. Analysis of Deamidation in Proteins Comprehensive Analytical Chemistry. 2008 52:375-410
   Google Scholar
• Stephenson RC, Clarke S. Succinimide formation from aspartyl and asparaginyl peptides as a model for the spontaneous degradation of proteins. J Biol Chem 1989; 264:6164 - 70; PMID: 2703484
   PubMed Web of Science ®Google Scholar
• Radkiewicz JL, Zipse H, Clarke S, Houk KN. Neighboring side chain effects on asparaginyl and aspartyl degradation: an ab initio study of the relationship between peptide conformation and backbone NH acidity. J Am Chem Soc 2001; 123:3499 - 506; http://dx.doi.org/10.1021/ja0026814; PMID: 11472122
   PubMed Web of Science ®Google Scholar
• Oliyai C, Patel JP, Carr L, Borchardt RT. Solid state chemical instability of an asparaginyl residue in a model hexapeptide. J Pharm Sci Technol 1994; 48:167 - 23; PMID: 8069519
   PubMedGoogle Scholar
• Oliyai C, Patel JP, Carr L, Borchardt RT. Chemical pathways of peptide degradation. VII. Solid state chemical instability of an aspartyl residue in a model hexapeptide. Pharm Res 1994; 11:901 - 8; http://dx.doi.org/10.1023/A:1018998312503; PMID: 7937533
   PubMed Web of Science ®Google Scholar
• Oliyai C, Borchardt RT. Chemical pathways of peptide degradation. VI. Effect of the primary sequence on the pathways of degradation of aspartyl residues in model hexapeptides. Pharm Res 1994; 11:751 - 8; http://dx.doi.org/10.1023/A:1018944800691; PMID: 8058648
   PubMed Web of Science ®Google Scholar
• Oliyai C, Borchardt RT. Chemical pathways of peptide degradation. IV. Pathways, kinetics, and mechanism of degradation of an aspartyl residue in a model hexapeptide. Pharm Res 1993; 10:95 - 102; http://dx.doi.org/10.1023/A:1018981231468; PMID: 8430066
   PubMed Web of Science ®Google Scholar
• Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem 1987; 262:785 - 94; PMID: 3805008
   PubMed Web of Science ®Google Scholar
• Clarke S. Propensity for spontaneous succinimide formation from aspartyl and asparaginyl residues in cellular proteins. Int J Pept Protein Res 1987; 30:808 - 21; http://dx.doi.org/10.1111/j.1399-3011.1987.tb03390.x; PMID: 3440704
   PubMedGoogle Scholar
• Xiao G, Bondarenko PV, Jacob J, Chu GC, Chelius D. 18O labeling method for identification and quantification of succinimide in proteins. Anal Chem 2007; 79:2714 - 21; http://dx.doi.org/10.1021/ac0617870; PMID: 17313184
   PubMed Web of Science ®Google Scholar
• Wakankar AA, Borchardt RT, Eigenbrot C, Shia S, Wang YJ, Shire SJ, et al. Aspartate isomerization in the complementarity-determining regions of two closely related monoclonal antibodies. Biochemistry 2007; 46:1534 - 44; http://dx.doi.org/10.1021/bi061500t; PMID: 17279618
   PubMed Web of Science ®Google Scholar
• Valliere-Douglass J, Wallace A, Balland A. Separation of populations of antibody variants by fine tuning of hydrophobic-interaction chromatography operating conditions. J Chromatogr A 2008; 1214:81 - 9; http://dx.doi.org/10.1016/j.chroma.2008.10.078; PMID: 19012891
   PubMed Web of Science ®Google Scholar
• Huang HZ, Nichols A, Liu D. Direct identification and quantification of aspartyl succinimide in an IgG2 mAb by RapiGest assisted digestion. Anal Chem 2009; 81:1686 - 92; http://dx.doi.org/10.1021/ac802708s; PMID: 19146457
   PubMed Web of Science ®Google Scholar
• Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, et al. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl 2001; 752:233 - 45; http://dx.doi.org/10.1016/S0378-4347(00)00548-X; PMID: 11270864
   PubMed Web of Science ®Google Scholar
• Chu GC, Chelius D, Xiao G, Khor HK, Coulibaly S, Bondarenko PV. Accumulation of succinimide in a recombinant monoclonal antibody in mildly acidic buffers under elevated temperatures. Pharm Res 2007; 24:1145 - 56; http://dx.doi.org/10.1007/s11095-007-9241-4; PMID: 17385019
   PubMed Web of Science ®Google Scholar
• Huang L, Lu J, Wroblewski VJ, Beals JM, Riggin RM. In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. Anal Chem 2005; 77:1432 - 9; http://dx.doi.org/10.1021/ac0494174; PMID: 15732928
   PubMed Web of Science ®Google Scholar
• Doyle HA, Zhou J, Wolff MJ, Harvey BP, Roman RM, Gee RJ, et al. Isoaspartyl post-translational modification triggers anti-tumor T and B lymphocyte immunity. J Biol Chem 2006; 281:32676 - 83; http://dx.doi.org/10.1074/jbc.M604847200; PMID: 16950786
   PubMed Web of Science ®Google Scholar
• Doyle HA, Gee RJ, Mamula MJ. Altered immunogenicity of isoaspartate containing proteins. Autoimmunity 2007; 40:131 - 7; http://dx.doi.org/10.1080/08916930601165180; PMID: 17453712
   PubMed Web of Science ®Google Scholar
• Young GW, Hoofring SA, Mamula MJ, Doyle HA, Bunick GJ, Hu Y, et al. Protein L-isoaspartyl methyltransferase catalyzes in vivo racemization of Aspartate-25 in mammalian histone H2B. J Biol Chem 2005; 280:26094 - 8; http://dx.doi.org/10.1074/jbc.M503624200; PMID: 15908425
   PubMed Web of Science ®Google Scholar
• Zhang Y, Martinez T, Woodruff B, Goetze A, Bailey R, Pettit D, et al. Hydrophobic interaction chromatography of soluble interleukin I receptor type II to reveal chemical degradations resulting in loss of potency. Anal Chem 2008; 80:7022 - 8; http://dx.doi.org/10.1021/ac800928z; PMID: 18707131
   PubMed Web of Science ®Google Scholar
• Boyd D, Kaschak T, Yan B. HIC resolution of an IgG1 with an oxidized Trp in a complementarity determining region. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879:955 - 60; http://dx.doi.org/10.1016/j.jchromb.2011.03.006; PMID: 21440514
   PubMed Web of Science ®Google Scholar
• Gong B, Wang L, Wang C, Geng X. Preparation of hydrophobic interaction chromatographic packings based on monodisperse poly(glycidylmethacrylate-co-ethylenedimethacrylate) beads and their application. J Chromatogr A 2004; 1022:33 - 9; http://dx.doi.org/10.1016/j.chroma.2003.09.063; PMID: 14753769
   PubMed Web of Science ®Google Scholar
• Kato Y, Nakatani S, Nakamura K, Kitamura T, Moriyama H, Hasegawa M, et al. Hydrophobicity gradient columns for the separation of trypsin inhibitor by hydrophobic interaction chromatography at low salt concentration. J Chromatogr A 2003; 986:83 - 8; http://dx.doi.org/10.1016/S0021-9673(02)01997-0; PMID: 12585325
   PubMed Web of Science ®Google Scholar
• Valliere-Douglass J, Jones L, Shpektor D, Kodama P, Wallace A, Balland A, et al. Separation and characterization of an IgG2 antibody containing a cyclic imide in CDR1 of light chain by hydrophobic interaction chromatography and mass spectrometry. Anal Chem 2008; 80:3168 - 74; http://dx.doi.org/10.1021/ac702245c; PMID: 18355059
   PubMed Web of Science ®Google Scholar
• Yan B, Steen S, Hambly D, Valliere-Douglass J, Vanden Bos T, Smallwood S, et al. Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain. J Pharm Sci 2009; 98:3509 - 21; http://dx.doi.org/10.1002/jps.21655; PMID: 19475547
   PubMed Web of Science ®Google Scholar
• Yin S, Pastuskovas CV, Khawli LA, Stults JT. Characterization of therapeutic monoclonal antibodies reveals differences between in vitro and in vivo time-course studies. Pharm Res 2013; 30:167 - 78; http://dx.doi.org/10.1007/s11095-012-0860-z; PMID: 22956170
   PubMed Web of Science ®Google Scholar
• Yu XC, Joe K, Zhang Y, Adriano A, Wang Y, Gazzano-Santoro H, et al. Accurate determination of succinimide degradation products using high fidelity trypsin digestion peptide map analysis. Anal Chem 2011; 83:5912 - 9; http://dx.doi.org/10.1021/ac200750u; PMID: 21692515
   PubMed Web of Science ®Google Scholar
• Zhao H, Graf O, Milovic N, Luan X, Bluemel M, Smolny M, et al. Formulation development of antibodies using robotic system and high-throughput laboratory (HTL). J Pharm Sci 2010; 99:2279 - 94; PMID: 20014026
   PubMed Web of Science ®Google Scholar
• Sukumar M, Doyle BL, Combs JL, Pekar AH. Opalescent appearance of an IgG1 antibody at high concentrations and its relationship to noncovalent association. Pharm Res 2004; 21:1087 - 93; http://dx.doi.org/10.1023/B:PHAM.0000032993.98705.73; PMID: 15290846
   PubMed Web of Science ®Google Scholar
• Hawe A, Hulse WL, Jiskoot W, Forbes RT. Taylor dispersion analysis compared to dynamic light scattering for the size analysis of therapeutic peptides and proteins and their aggregates. Pharm Res 2011; 28:2302 - 10; http://dx.doi.org/10.1007/s11095-011-0460-3; PMID: 21560019
   PubMed Web of Science ®Google Scholar
• Hawe A, Friess W, Sutter M, Jiskoot W. Online fluorescent dye detection method for the characterization of immunoglobulin G aggregation by size exclusion chromatography and asymmetrical flow field flow fractionation. Anal Biochem 2008; 378:115 - 22; http://dx.doi.org/10.1016/j.ab.2008.03.050; PMID: 18455994
   PubMed Web of Science ®Google Scholar
• Bermudez O, Forciniti D. Aggregation and denaturation of antibodies: a capillary electrophoresis, dynamic light scattering, and aqueous two-phase partitioning study. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 807:17 - 24; http://dx.doi.org/10.1016/j.jchromb.2004.01.029; PMID: 15177155
   PubMed Web of Science ®Google Scholar